A Study of T3 Therapy in Patients With Hypothyroidism

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 15% of the time (7,397 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancertherapyhormoneestrogenlife
  Phrases that lowered it: dailymultiplesinglemedicaldiabetes
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 47.2% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 1 (raises risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 3.3% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Maximum age: 65 (lowers risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 347 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports before start: 1655 (raises risk) · Drug's FDA history
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects NCT01581463 · started 2012 · scored riskier than 5% of active trials completed
• Identification of Non-responders to Levothyroxine Therapy NCT03627611 · started 2018 · scored riskier than 13% of active trials completed
• Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients NCT03053115 · started 2017 · scored riskier than 17% of active trials completed
• Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma NCT03787303 · started 2019 · scored riskier than 98% of active trials terminated
• A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants NCT04124705 · started 2019 · scored riskier than 14% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.